US64135M1053 - Common Stock
NEUROGENE INC
NASDAQ:NGNE (11/4/2024, 8:26:12 PM)
After market: 68.8599 +2.86 (+4.33%)66
+19.93 (+43.26%)
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company is headquartered in New York City, New York and currently employs 91 full-time employees. The company went IPO on 2014-03-07. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is under development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in pediatric female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. The company is also developing NGN-101 for the treatment of CLN5 Batten disease.
NEUROGENE INC
535 W 24Th Street, 5Th Floor
New York City NEW YORK
P: 18772375020
Employees: 91
Website: https://www.neurogene.com/
Monday's session: top gainers and losers
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.
Stay updated with the stocks that are on the move in Monday's pre-market session.
Here you can normally see the latest stock twits on NGNE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: